Denali Therapeutics Inc. (DNLI)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
26.48 USD
+0.80
(3.115%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 26.16 -0.32 (-0.320%) ⇩ (July 13, 2026, 7:49 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:12 a.m. EDT
The investment case here is fractured by a brutal multi-year decline. Despite a recent rally and glowing headlines about institutional backing, the underlying business has suffered four consecutive years of negative annual returns, dragging the total trajectory down significantly. This persistent price erosion suggests the market sees severe structural issues that outweigh any recent catalysts. The balance sheet is technically healthy with massive cash reserves, but the company is burning cash rapidly with negative free cash flow and no dividend to offset the drag. On the short end, the options market is screaming 'sell,' with put buyers dominating the landscape and pricing in a move toward the lower end of the range. The statistical forecast is weak and contradicts the strong momentum seen recently, but given the deep value trap characteristics of the long-term chart, caution is warranted. This is a speculative biotech play with high binary risk, currently priced for disappointment. |
| Model | MAE |
|---|---|
| MSTL_70_126 ✓ | 0.081807 |
| MSTL_126 | 0.084828 |
| MSTL_70 | 0.086482 |
| MSTL | 0.091922 |
| AutoETS | 0.092232 |
| AutoARIMA | 0.092534 |
| AutoTheta | 0.095978 |
Forecast horizon: 60 days | Selected: MSTL_70_126
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 1.79 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.285 |
| Excess Kurtosis | -0.40 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.324 |
| Market Cap | 4,202,633,984 |
| Forward P/E | -10.67 |
| Beta | 0.96 |
| Website | https://www.denalitherapeutics.com |
As of July 11, 2026, 5:12 a.m. EDT: Speculators are aggressively positioning for a downside scenario. Put volume and open interest vastly exceed call volume across all expirations, particularly in the September and December windows where out-of-the-money puts dominate. While there is some call activity at lower strikes (10-17.5), the overwhelming capital flow is into protection against a drop to the $10-$15 range, suggesting a consensus view of significant near-term weakness.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.74812794 |
| Address1 | 161 Oyster Point Boulevard |
| All Time High | 93.94 |
| All Time Low | 10.57 |
| Ask | 32.03 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 2,045,580 |
| Average Daily Volume3 Month | 1,812,600 |
| Average Volume | 1,812,600 |
| Average Volume10Days | 2,045,580 |
| Beta | 0.963 |
| Bid | 19.08 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 5.837 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 26.48 |
| Current Ratio | 9.285 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 26.6 |
| Day Low | 24.77 |
| Debt To Equity | 4.324 |
| Display Name | Denali Therapeutics |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | -531,758,016 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.121 |
| Enterprise Value | 3,254,996,736 |
| Eps Current Year | -2.31513 |
| Eps Forward | -2.48202 |
| Eps Trailing Twelve Months | -2.97 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 21.5478 |
| Fifty Day Average Change | 4.9321995 |
| Fifty Day Average Change Percent | 0.22889574 |
| Fifty Two Week Change Percent | 74.81279 |
| Fifty Two Week High | 27.3 |
| Fifty Two Week High Change | -0.8199997 |
| Fifty Two Week High Change Percent | -0.030036619 |
| Fifty Two Week Low | 12.58 |
| Fifty Two Week Low Change | 13.9 |
| Fifty Two Week Low Change Percent | 1.1049285 |
| Fifty Two Week Range | 12.58 - 27.3 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,512,743,400,000 |
| Float Shares | 144,232,235 |
| Forward Eps | -2.48202 |
| Forward P E | -10.66873 |
| Free Cashflow | -190,330,368 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 507 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -406,396,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.09159 |
| Held Percent Institutions | 1.05084 |
| Implied Shares Outstanding | 158,709,737 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. |
| Long Name | Denali Therapeutics Inc. |
| Market | us_market |
| Market Cap | 4,202,633,984 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_301283598 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -508,016,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,075,666,046 |
| Number Of Analyst Opinions | 15 |
| Open | 25.69 |
| Operating Cashflow | -412,336,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 650 866 8547 |
| Post Market Change | -0.3199997 |
| Post Market Change Percent | -1.2084581 |
| Post Market Price | 26.16 |
| Post Market Time | 1,783,986,584 |
| Previous Close | 25.68 |
| Price Eps Current Year | -11.437802 |
| Price Hint | 2 |
| Price To Book | 4.536577 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.981 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.15789 |
| Region | US |
| Regular Market Change | 0.799999 |
| Regular Market Change Percent | 3.11526 |
| Regular Market Day High | 26.6 |
| Regular Market Day Low | 24.77 |
| Regular Market Day Range | 24.77 - 26.6 |
| Regular Market Open | 25.69 |
| Regular Market Previous Close | 25.68 |
| Regular Market Price | 26.48 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,894,461 |
| Return On Assets | -0.26953 |
| Return On Equity | -0.49592 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 158,709,737 |
| Shares Percent Shares Out | 0.1005 |
| Shares Short | 15,949,089 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 14,990,471 |
| Short Name | Denali Therapeutics Inc. |
| Short Percent Of Float | 0.10609999 |
| Short Ratio | 7.67 |
| Source Interval | 15 |
| State | CA |
| Symbol | DNLI |
| Target High Price | 42.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 33.93333 |
| Target Median Price | 35.0 |
| Total Cash | 987,683,968 |
| Total Cash Per Share | 6.223 |
| Total Debt | 40,047,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.97 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 19.171925 |
| Two Hundred Day Average Change | 7.308075 |
| Two Hundred Day Average Change Percent | 0.3811863 |
| Type Disp | Equity |
| Volume | 1,894,461 |
| Website | https://www.denalitherapeutics.com |
| Zip | 94,080 |